ONKOLOGIE / Onkologie. 2024;18(2):103-108 / www.onkologiecs.cz 108 HLAVNÍ TÉMA Aktuální postavení CAR T-lymfocytů v terapii non-Hodgkinských lymfomů LITERATURA 1. Duell J, Lurati S, Dittrich M, et al. First Generation Chimeric Antigen Receptor Display Functional Defects In Key Signal Pathways Upon Antigen Stimulation. Blood (Internet). 2010;116:2088 LP-2088. Available from: http://www.bloodjournal.org/content/116/21/2088.abstract. 2. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388-398. 3. O’Brien S, Nastoupil LJ, Essell J, et al. A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study). Blood (Internet). 2022;140:9457-9458. Available from: https://doi. org/10.1182/blood-2022-168128. 4. Sahillioglu AC, Schumacher TN. Safety switches for adoptive cell therapy. Curr Opin Immunol (Internet). 2022;74:190198. Available from: https://www.sciencedirect.com/science/article/pii/S0952791521000893. 5. Benmebarek M-R, Karches CH, Cadilha BL, et al. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20. 6. Spiegel JY, Sahaf B, Hossain N, et al. Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. Blood (Internet). 2018;132:576 LP-576. Available from: http:// www.bloodjournal.org/content/132/Suppl_1/576.abstract. 7. Murthy H, Iqbal M, Chavez JC, et al. Cytokine Release Syndrome: Current Perspectives. ImmunoTargets Ther. 2019;8:43-52. 8. Mucha SR, Rajendram P. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. Curr. Oncol. 2023; p. 5003-5023. 9. Jung S, Greiner J, von Harsdorf S, et al. Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood Adv. 2021;5:3789-3793. 10. Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haemato. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. England; 2022; p. 259-275. 11. Asokan S, Cullin N, Stein-Thoeringer CK, et al. CAR-T Cell Therapy and the Gut Microbiota. Cancers (Basel). 2023;15. 12. Park JH, Sauter CS, Palomba ML, et al. A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. Blood (Internet). 2021;138:96. Available from: https://doi.org/10.1182/blood-2021-150431. 13. Hanna KS, Kaur H, Alazzeh MS, et al. Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review. Cureus. 2022;14:e28162. 14. Rejeski K, Wang Y, Hansen DK, et al. Applying the EHA/ EBMT Grading for ICAHT after CAR-T: Comparative Incidence and Association with Infections and Mortality. Blood Adv. 2024. 15. Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023;7:6589-6598. 16. Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/ refractory large B-cell lymphoma. Blood. 2021;138:2499-2513. 17. Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood (Internet). 2023;142:865-877. Available from: https://doi.org/10.1182/ blood.2023020578. 18. Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607-5615. 19. Jaeger U, Bishop MR, Salles G, et al. Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial. Blood (Internet). 2020;136:48-49. Available from: https://doi.org/10.1182/blood-2020-137045. 20. Locke FL, Oluwole OO, Kuruvilla J, et al. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi- -Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7. Blood (Internet). 2022;140:638-640. Available from: https:// doi.org/10.1182/blood-2022-158492. 21. Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood (Internet). 2018;132:91 LP-91. Available from: http://www.bloodjournal.org/content/132/ Suppl_1/91.abstract. 22. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386:640-654. 23. Iacoboni G, Navarro V, Martín-López AÁ, et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:205-217. 24. Greenbaum U, Hashmi H, Elsawy M, et al. Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART). Blood (Internet). 2022;140:4636-4638. Available from: https:// doi.org/10.1182/blood-2022-169452. 25. Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood (Internet). 2019;134:766. Available from: https://doi. org/10.1182/blood-2019-130983. 26. Yassine F, Iqbal M, Murthy H, et al. Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Curr Res Transl Med (Internet). 2020;68:159170. Available from: https://www.sciencedirect.com/science/ article/pii/S2452318620300386. 27. Jacobson C, Locke FL, Ghobadi A, et al. Long-Term (≥ 4 Year and ≥ 5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). Blood (Internet). 2021;138:1764. Available from: https://doi. org/10.1182/blood-2021-148078. 28. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol (Internet). 2021;22:1403-1415. Available from: https://doi. org/10.1016/S1470-2045(21)00375-2. 29. Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145-2154. 30. Kwon M, Iacoboni G, Reguera JL, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica (Internet). 2022;108:110-121. Available from: https://haematologica.org/ article/view/haematol.2022.280805. 31. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysi. Lancet (Internet). 2022;399:2294-2308. Available from: https://doi.org/10.1016/S0140-6736(22)00662-6. 32. Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021;386:629-639. 33. Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med (Internet). 2023;29:2593-2601. Available from: https://doi.org/10.1038/s41591-023-02572-5. 34. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol (Internet). 2022;23:1066-1077. Available from: https://doi.org/10.1016/ S1470-2045(22)00339-4. 35. Ayuk F, Gagelmann N, von Tresckow B, et al. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. Blood Adv (Internet). 2023;7:5316-5319. Available from: https://doi.org/10.1182/bloodadvances.2023010336. 36. Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32-39. 37. Jacobson CA, Falvey C, Bouvier R, et al. A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL). Blood (Internet). 2022;140:1060-1061. Available from: https://doi.org/10.1182/blood-2022-165256. 38. Chavez JC, Dickinson M, Munoz JL, et al. 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). Blood (Internet). 2023;142:894. Available from: https://doi.org/10.1182/ blood-2023-174510. 39. Ghione P, Palomba ML, Ghesquieres H, et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica (Internet). 2022;108:822-832. Available from: https://haematologica.org/article/view/haematol.2022.281421. 40. Rodgers TD, Casulo C, Boissard F, et al. Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies. Oncol Ther (Internet). 2021;9:329-346. Available from: https://doi.org/10.1007/s40487-021-00161-5. 41. Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325-332. 42. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol (Internet). 2022;23:91-103. Available from: https://doi.org/10.1016/S1470-2045(21)00591-X. 43. Morschhauser F, Dahiya S, Palomba ML, et al. TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS (PTS) WITH RELAPSED/ REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). Hematol Oncol (Internet). 2023;41:877-880. Available from: https://doi. org/10.1002/hon.3196_LBA4. 44. Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol (Internet). 2022;JCO.21.02370. Available from: https://doi.org/10.1200/JCO.21.02370. Další literatura u autorky a na www.onkologiecs.cz
RkJQdWJsaXNoZXIy NDA4Mjc=